Diabetic kidney disease: Act now or pay later
Abstract
For the 2010 International Society of Nephrology/International Federation of Kidney Foundations World Kidney Day Steering Committee (RA) and the International Diabetes Federation (PZ) World Kidney Day 11 March 2010: we must act on diabetic kidney disease
References
1. International Diabetes Federation and International Society of Nephrology, Diabetes and kidney disease: time to act. 2003: Brussels.
2. Zimmet P., Alberti K., Shaw J. Global and societal implications of the diabetes epidemic // Nature. 2001. Vol. 414. P. 782–787.
3. King H., Aubert R., Herman W. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections // Diabetes Care. 1998. Vol. 21. P. 1414–1431.
4. Yoon K. et al. Epidemic obesity and type 2 diabetes in Asia // Lancet. 2006. Vol. 368. P. 1681–1688.
5. Sicree R., Shaw J., Zimmet P. Diabetes and impaired glucose tolerance // Diabetes Atlas. 3rd edition. Gan D., Editor. International Diabetes Federation: Brussels, 2006. P. 15–109.
6. Reutens A.T., Prentice L., Atkins R. The Epidemiology of Diabetic Kidney Disease // The Epidemiology of Diabetes Mellitus. 2nd Edition. Ekoé J. et al. Editors. 2008, John Wiley & Sons Ltd: Chichester.499–518.
7. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. International comparisons, in 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2007, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda. P. 239–254.
8. Appendix II, in ANZDATA Registry Report 2008. McDonald S., Excell L., Livingston B., Editors. 2008, Australia and New Zealand Dialysis and Transplant Registry: Adelaide. P. 1–97.
9. Yamagata K. et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening // Clin Exp Nephrol. 2008. Vol. 12. P. 1–8.
10. Lysaght M. Maintenance dialysis population dynamics: Current trends and long term implications // J Am Soc Nephrol. 2002. Vol. 13. P. S37–40.
11. Adler A. et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) // Kidney Int. 2003. Vol. 63. P. 225–232.
12. Retnakaran R. et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74 // Diabetes. 2006. Vol. 55 (6). P. 1832–1839.
13. Parving H. et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective // Kidney Int. 2006. Vol. 69 (11). P. 2057–2063.
14. Ninomiya T. et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes // J Am Soc Nephrol. 2009. Vol. 20 (8). P. 1813–1821.
15. Dunstan D. et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study // Diabetes Care. 2002. Vol. 25 (5). P. 829–834.
16. White S. et al. Limited knowledge of kidney disease in a survey of AusDiab study participants // Med J Aust. 2008. Vol. 188 (4). P. 204–208.
17. Whaley-Connell A. et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) // Am J Kidney Dis. 2009. Vol. 53 (Suppl. 4). P. S11–21.
18. Thomas M., Viberti G., Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point? // Nat Clin Pract Nephrol. 2008. Vol. 4 (1). P. 2–3.
19. Holman R. et al. 10-year follow-up of intensive glucose control in type 2 diabetes // N Engl J Med. 2008. Vol. 359 (15). P. 1577–1589.
20. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? // Diabet Med. 2008. Vol. 25 (Suppl. 2). P. 25–29.
21. Gaede P. et al. Effect of a multifactorial intervention on mortality in type 2 diabetes // N Engl J Med. 2008. Vol. 358 (6). P. 580–591.
22. Patel A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial // Lancet. 2007. Vol. 370. P. 829–840.
23. Group A.C. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N Engl J Med. 2008. Vol. 358. P. 2560–2572.
24. Zoungas S. et al. The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE // Diabetes Care. 2009. Aug 3 [Epub ahead of print].
25. Ruggenenti P. et al. Preventing microalbuminuria in type 2 diabetes // N Engl J Med. 2004. Vol. 351 (19). P. 1941–1951.
26. Parving H. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // N Engl J Med. 2001. Vol. 345 (12). P. 870–878.
27. Lewis E. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N Eng J Med. 2001. Vol. 345. P. 851–860.
28. Burney B., Kalaitzidis R., Bakris G. Novel therapies of diabetic nephropathy // Curr Opin Nephrol Hypertens. 2009. Vol. 18 (2).107–111.
Review
For citations:
Atkins R.C., Zimmet P. Diabetic kidney disease: Act now or pay later. Nephrology and Dialysis. 2009;11(4):272-274. (In Russ.)
Views:
8
Email this article 